Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503121 | 0.90 | TLR7 (0.44) | TLR7KMT2AMAPTMEN1TLR8 | |
| SCHEMBL21566196 | 0.85 | TLR7 (0.40) | TLR7TDP1L3MBTL1KMT2AMAPT | |
| SCHEMBL19475350 | 0.84 | TLR7 (0.46) | TLR7TDP1L3MBTL1KMT2AMAPT | |
| SCHEMBL28478082 | 0.80 | TLR7 (0.37) | TLR7TDP1L3MBTL1KMT2AMAPT | |
| SCHEMBL30598791 | 0.80 | TLR7 (0.37) | TLR7TDP1L3MBTL1KMT2AMAPT | |
| SCHEMBL19475179 | 0.79 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL26981077 | 0.78 | TLR7 (0.59) | TLR7TLR8RXFP1 | |
| SCHEMBL22445197 | 0.76 | AGTR1 (0.42) | TLR7KMT2AMAPTMEN1TLR8 | |
| SCHEMBL22017902 | 0.76 | PIK3CD (0.47) | TLR7TDP1L3MBTL1KMT2AMAPT | |
| SCHEMBL20475984 | 0.75 | KCNH2 (0.42) | KMT2AMAPTMEN1MAPK8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184746-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | TLR7 161/4885TDP1 302/4885L3MBTL1 845/4885 |
| US-20200157097-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | TLR7 161/4885TDP1 302/4885L3MBTL1 845/4885 |
| US-10556903-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | TLR7 161/4885TDP1 302/4885L3MBTL1 845/4885 |
| US-20190127367-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | TLR7 207/4885TDP1 589/4885L3MBTL1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.